Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aclaris Therapeutics (ACRS) Current Deferred Revenue (2024 - 2025)

Historic Current Deferred Revenue for Aclaris Therapeutics (ACRS) over the last 2 years, with Q3 2025 value amounting to $3.9 million.

  • Aclaris Therapeutics' Current Deferred Revenue rose 424.97% to $3.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.9 million, marking a year-over-year increase of 424.97%. This contributed to the annual value of $3.9 million for FY2024, which is N/A changed from last year.
  • Aclaris Therapeutics' Current Deferred Revenue amounted to $3.9 million in Q3 2025, which was up 424.97% from $3.9 million recorded in Q2 2025.
  • Aclaris Therapeutics' 5-year Current Deferred Revenue high stood at $3.9 million for Q3 2025, and its period low was $3.8 million during Q3 2024.